Literature DB >> 590312

The influence of prolonged treatment with D-penicillamine on the immune response in Wilson's disease.

A Czlonkowska.   

Abstract

Humoral and cell-mediated immunity were studied in a group of patients with Wilson's disease not previously treated with D-penicillamine, and in a group of patients treated with the drug for more than two years. The previously untreated patients showed an exaggerated humoral immune response, i. e. increased levels of IgG and, IgM, higher titer of antibodies to Kunin's antigen, and depression of cell-mediated immunity, namely a decreased response to DNCB, decreased lymphocyte transformation after stimulation with Con A, PPD, Candida and streptokinase and a reduced response to streptokinase in the MIF test. After treatment the humoral response returned to normal, and in the case of IgA and antibodies to S. typhi O antigen, it even dropped below normal values. The cell-mediated immune response returned to normal with the exception of lymphocyte transformation by PHA and Candida albicans. In in vitro studies it was found that D-penicillamine had no influence on lymphocyte transformation when PHA and Con A were used as mitogens. With PPD as antigen, lymphocyte stimulation and migration inhibition were inhibited by concentrations of penicillamine ranging from 6 to 1000 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 590312     DOI: 10.1007/bf00607425

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

2.  Penicillamine--an Anglo-American adventure in the treatment of rheumatoid arthritis.

Authors:  I A Jaffe
Journal:  N Engl J Med       Date:  1973-03-22       Impact factor: 91.245

3.  [Immunologic dysfunction in hepatolenticular degeneration].

Authors:  A Czlonkowska
Journal:  Neurol Neurochir Pol       Date:  1973 Mar-Apr       Impact factor: 1.621

4.  The effects of penicillamine on lymphocytes in culture.

Authors:  S Roath; R Wills
Journal:  Postgrad Med J       Date:  1974-08       Impact factor: 2.401

5.  [Cuprenil in the treatment of rheumatoid arthritis].

Authors:  B Bogdanikowa; J Rudy; K Bernacka; A Stasiewicz
Journal:  Pol Tyg Lek       Date:  1973-07-02

6.  Suppression of adjuvant arthritis by penicillamine in pyridoxine deficient rats.

Authors:  R Baumgartner; H Obenaus; H C Stoerk
Journal:  Proc Soc Exp Biol Med       Date:  1974-05

7.  Observations on copper metabolism in Wilson's disease.

Authors:  A Czlonkowska; A Galewicz; M Rodo; H Wehr
Journal:  Acta Univ Carol Med Monogr       Date:  1973

8.  [Preliminary results of treatment of chronic aggressive hepatitis with d-penicillamine (Cuprenil Polfa)].

Authors:  M Eisner; J Goertz; H Dobrohorska; I Bohdanowicz
Journal:  Pol Tyg Lek       Date:  1973-10-29

9.  Studies with 35S-labelled DL-penicillamine in patients with Wilson's disease.

Authors:  K Gibbs; J M Walshe
Journal:  Q J Med       Date:  1971-04

10.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09
View more
  2 in total

1.  Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period.

Authors:  A Członkowska; B Tarnacka; T Litwin; J Gajda; M Rodo
Journal:  J Neurol       Date:  2005-03-02       Impact factor: 4.849

2.  Autoantibodies in Wilson disease: Impact on clinical course.

Authors:  Magdalena Antczak-Kowalska; Anna Członkowska; Ceren Eyileten; Anna Palejko; Agnieszka Cudna; Marta Wolska; Agnieszka Piechal; Tomasz Litwin
Journal:  JIMD Rep       Date:  2022-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.